These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29790125)

  • 21. [Not Available].
    Simeon L; Wuillemin WA
    Ther Umsch; 2016; 73(10):561-566. PubMed ID: 28045358
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
    BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding: Characteristics, Reversal Strategies, and Outcomes From a Multicenter Observational Study.
    Xu Y; Schulman S; Dowlatshahi D; Holbrook AM; Simpson CS; Shepherd LE; Wells PS; Giulivi A; Gomes T; Mamdani M; Khuu W; Frymire E; Johnson AP;
    Chest; 2017 Jul; 152(1):81-91. PubMed ID: 28219635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of bleeding in patients treated with direct oral anticoagulants.
    Levi M
    Crit Care; 2016 Aug; 20():249. PubMed ID: 27543264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.
    Vinogradova Y; Coupland C; Hill T; Hippisley-Cox J
    BMJ; 2018 Jul; 362():k2505. PubMed ID: 29973392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
    Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
    Curr Med Res Opin; 2017 Oct; 33(10):1745-1754. PubMed ID: 28849676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States.
    Lip GY; Pan X; Kamble S; Kawabata H; Mardekian J; Masseria C; Bruno A; Phatak H
    Int J Clin Pract; 2016 Sep; 70(9):752-63. PubMed ID: 27550177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
    Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L
    Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of the efficacy and safety of new oral anticoagulant drugs in the secondary stroke prevention in patients with AF: single center experience based on 311 patients.
    Lasek-Bal A; Urbanek T; Gierek D
    Int Angiol; 2015 Dec; 34(6):552-61. PubMed ID: 25410296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Laboratory measurement of the direct oral anticoagulants: Indications and impact on management in clinical practice.
    Wright C; Brown R; Cuker A
    Int J Lab Hematol; 2017 May; 39 Suppl 1():31-36. PubMed ID: 28447413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
    Bundhun PK; Soogund MZ; Teeluck AR; Pursun M; Bhurtu A; Huang WQ
    BMC Cardiovasc Disord; 2017 Jan; 17(1):15. PubMed ID: 28056795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.
    Kohsaka S; Murata T; Izumi N; Katada J; Wang F; Terayama Y
    Curr Med Res Opin; 2017 Nov; 33(11):1955-1963. PubMed ID: 28857611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale.
    Douketis JD; Spyropoulos AC; Anderson JM; Arnold DM; Bates SM; Blostein M; Carrier M; Caprini JA; Clark NP; Coppens M; Dentali F; Duncan J; Gross PL; Kassis J; Kowalski S; Lee AY; Le Gal G; Le Templier G; Li N; MacKay E; Shah V; Shivakumar S; Solymoss S; Spencer FA; Syed S; Tafur AJ; Vanassche T; Thiele T; Wu C; Yeo E; Schulman S
    Thromb Haemost; 2017 Dec; 117(12):2415-2424. PubMed ID: 29212129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Burden of Inappropriate Prescription of Direct Oral Anticoagulants at Hospital Admission and Discharge in the Elderly: A Prospective Observational Multicenter Study.
    Bruneau A; Schwab C; Anfosso M; Fernandez C; Hindlet P
    Drugs Aging; 2019 Nov; 36(11):1047-1055. PubMed ID: 31486994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study.
    Viktil KK; Lehre I; Ranhoff AH; Molden E
    Drugs Aging; 2019 Jan; 36(1):65-71. PubMed ID: 30411284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents.
    Sciascia S; Radin M; Schreiber K; Fenoglio R; Baldovino S; Roccatello D
    Intern Emerg Med; 2017 Dec; 12(8):1101-1108. PubMed ID: 28929298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticoagulation prescribing patterns in patients with cancer.
    Xiang E; Ahuja T; Raco V; Cirrone F; Green D; Papadopoulos J
    J Thromb Thrombolysis; 2018 Jan; 45(1):89-98. PubMed ID: 29052104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
    Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
    Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.